BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home
»
Authors
» Nuala Moran
Nuala Moran
Articles
ARTICLES
Vernalis Seeks Second Nasdaq Listing, Reports Profitability
March 27, 2002
By
Nuala Moran
ReGen’s Phase IIa Interim Data Not Significant In Alzheimer’s
March 27, 2002
By
Nuala Moran
Cyclacel, University Of Edinburgh Form Drug Design Collaboration
March 27, 2002
By
Nuala Moran
Avidex Platform Creates TCRs; Company Planning Partnerships
March 27, 2002
By
Nuala Moran
Cyclacel, University Of Edinburgh Form Drug Design Collaboration
March 27, 2002
By
Nuala Moran
Avidex Platform Creates TCRs; Company Planning Partnerships
March 27, 2002
By
Nuala Moran
ReGen’s Phase IIa Interim Data Not Significant In Alzheimer’s
March 27, 2002
By
Nuala Moran
Vernalis Seeks Second Nasdaq Listing, Reports Profitability
March 27, 2002
By
Nuala Moran
PPL’s AAT Facing Further Delays; Launch Pushed Back
March 20, 2002
By
Nuala Moran
Powderject Sells Needle-Free Drug Delivery Business To AlgoRx
March 20, 2002
By
Nuala Moran
View All Articles by Nuala Moran